Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit. Overall product ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
Clade I, the version of mpox now circulating in Southern California, is not new to science. It’s been responsible for severe ...
There’s a long, proud tradition of gay people getting straights together, but in the past 20 years, we’ve seen some primo ...
Everyday Health on MSN
Viral Infections Can Triple the Risk of Heart Attack and Stroke
COVID triples the risk of a heart attack, researchers say, while flu quadruples the risk. Shingles, HIV, and hepatitis C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback